Literature DB >> 7105009

Chromosomal changes associated with progression of the Dunning R-3327 rat prostatic adenocarcinoma system.

N Wake, J Isaacs, A A Sandberg.   

Abstract

Several distinct sublines have developed upon serial passages of the original Dunning R-3327-H rat prostatic tumor. These tumors, each in different progressional stages, have been examined cytogenetically in the present study in order to explore the role of chromosomal changes in tumorigenesis. The original parent H tumor, from which all the other tumors were derived, has a normal karyotype, suggesting that visible alterations in chromosome structure are not essential in the early stages of the tumor. Nonrandom involvement of chromosome 4 in abnormalities observed in the increasingly aberrant tumors derived from the H tumor indicates that chromosomes most often affected may carry genetic material which is important in the regulation of cell proliferation and that this genetic material needs to undergo changes in the process of malignant transformation. Cytogenetic analysis of the Dunning sublines as a group indicated that the karyotypes of the tumors in later progressional stages tend to deviate more from the normal than those found in earlier stages. Comparison of chromosomal changes and phenotypic characteristics observed in this series of tumors suggested that the growth rate, dedifferentiation, and attainment of metastatic ability were related to the chromosome variation. The appearance and clonal development of tumor cells with a typical translocation, i.e. t(4;7), accelerated tumor growth rates of the differentiated tumors. Duplication of chromosomes was associated with a markedly increased growth rate and dedifferentiation of tumor cells in the anaplastic tumors. In addition, chromosomal loss from tetraploidy and development of complex rearrangements were associated with attainment of metastatic ability. These results point to the importance of chromosome changes in the development and biology of tumors.

Entities:  

Mesh:

Year:  1982        PMID: 7105009

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  The effect of a combination of zindoxifene and cisplatin on Dunning R3327-G prostatic carcinomas of the rat.

Authors:  E von Angerer; H Birnböck; M Kager; A Maucher
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 2.  Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault.

Authors:  J T Arnold; J T Isaacs
Journal:  Endocr Relat Cancer       Date:  2002-03       Impact factor: 5.678

Review 3.  Studies on rat mammary adenocarcinomas: a model for metastasis.

Authors:  I A Ramshaw; P Badenoch-Jones
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

Review 4.  Implications of tumor progression on clinical oncology.

Authors:  D R Welch; S P Tomasovic
Journal:  Clin Exp Metastasis       Date:  1985 Jul-Sep       Impact factor: 5.150

Review 5.  Molecular and cellular markers for metastatic prostate cancer.

Authors:  C W Rinker-Schaeffer; W B Isaacs; J T Isaacs
Journal:  Cancer Metastasis Rev       Date:  1993-03       Impact factor: 9.264

6.  Chromosome and DNA analyses of rat 13762NF mammary adenocarcinoma cell lines and clones of different metastatic potentials.

Authors:  V Pearce; S Pathak; D Mellard; D R Welch; G L Nicolson
Journal:  Clin Exp Metastasis       Date:  1984 Oct-Dec       Impact factor: 5.150

Review 7.  Somatic cell fusion as a source of genetic rearrangement leading to metastatic variants.

Authors:  L Larizza; V Schirrmacher
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

8.  Influence of tumor transplantation methods on tumor growth rate and metastatic potential of solitary tumors derived from metastases.

Authors:  J P Volpe; L Milas
Journal:  Clin Exp Metastasis       Date:  1990 Jul-Aug       Impact factor: 5.150

Review 9.  Development of androgen-independent tumor cells and their implication for the treatment of prostatic cancer.

Authors:  J T Isaacs; N Kyprianou
Journal:  Urol Res       Date:  1987

10.  Decrease in the AgNOR number in Dunning R3327 prostate cancers after treatment with an agonist and antagonist of luteinizing hormone-releasing hormone.

Authors:  K Szepeshazi; E Korkut; A V Schally
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.